Table 1.
HLA-DR3-restricted T cell responses and HLA-DR3 binding of hsp65-derived peptides in humans or HLA-DR3.Ab0 mice
| hsp65 amino acid sequence | Recognition by HLA-DR3-restricted T cells*
|
HLA-DR3 binding affinity, IC50, μM† | |
|---|---|---|---|
| In humans | In tg mice | ||
| 1-20 MAKTIAYDEEARRGLERGLN | +++ | +++ | 0.06 |
| 41-60 KKWGAPTITNDGVSIAKEIE | − | − | 0.3 |
| 511-530 FLTTEAVVADKPEKEKASVP | − | − | 0.7 |
| 201-220 YFVTDPERQEAVLEDPYILL | − | − | 1.3 |
| 281-300 DRRKAMLQDMAILTGGQVIS | − | − | 1.7 |
| 211-230 AVLEDPYILLVSSKVSTVKD | − | − | 2 |
| 241-260 AGKPLLIIAEDVEGEALSTL | − | − | 2 |
| 481-500 VYEDLLAAGVADPVKVTRSA | − | − | 2.6 |
| 261-280 VVNKIRGTFKSVAVKAPGFG | − | − | 5 |
| 81-100 DDVAGDGTTTATVLAQALVR | − | − | 6.5 |
| 181-200 FGLQLELTEGMRFDKGYISG | − | − | 9 |
| 321-340 VVVTKDETTIVEGAGDTDAI | − | − | 14 |
| 191-210 MRFDKGYISGYFVTDPERQE | − | − | 19 |
| 341-360 AGRVAQIRQEIENSDSDYDR | − | − | 20 |
| 401-420 AKAAVEEGIVAGGGVTLLQA | − | − | 20 |
| 441-460 KVALEAPLKQIAFNSGLEPG | − | − | 22 |
| 491-510 ADPVKVTRSALQNAASIAGL | − | − | 22 |
| 301-320 EEVGLTLENADLSLLGKARK | − | − | 25 |
| 171-190 GVITVEESNTFGLQLELTEG | − | + | 26 |
| 331-350 VEGAGDTDAIAGRVAQIRQE | − | − | 28 |
| 31-50 GPKGRNVVLEKKWGAPTITN | − | − | 30 |
| All other peptides | − | − | >100 |
DR3.Ab0 mice were immunized with BCG and hsp65 (10 μg per mouse). After 7 days, LNCs were challenged in vitro with hsp65− peptide (50 μg/ml).
*
Results for hsp65-reactive human T cells are shown for reference purposes only (see ref. 19). +++ indicates SI (stimulation index) ≥ 4; + indicates 2 ≤ SI ≤ 3; − indicates SI < 2.
†
Peptide binding affinity (IC50) was defined as high-affinity (<1 μM), intermediate-affinity (1 μM to 10 μM), weak-affinity (10 μM to 100 μM), or nonbinding (>100 μM), according to ref. 27.